**Saturated fatty acids induce lipotoxicity in lymphatic endothelial cells contributing to secondary lymphedema development**

Karina P. Gomes1, Jacob Korodimas1, Emily Liu1,Nirav Patel1, Xiaoyan Yang1, Susan Goruk2, Jaqueline Munhoz2, Catherine J. Field2 and Spencer B. Gibson1\*

1Department of Oncology, University of Alberta; Edmonton, Canada.

2Department of Agricultural, Food and Nutritional Science; University of Alberta, Edmonton, Canada.

\*Corresponding author: [sgibson2@ualberta.ca](mailto:sgibson2@ualberta.ca)

**Abstract**

Lymphedema is a chronic lymphatic disorder characterized by persistent tissue swelling, pain, and recurrent infections, often secondary to cancer treatment, surgery, or obesity. Obesity-associated increases in saturated fatty acids (SFAs) have been linked to lipotoxicity. In this study, patients with secondary lymphedema showed a significantly lower plasma polyunsaturated to saturated fatty acid (PUFA/SFA) ratio compared to BMI-matched controls. Stearic acid, a common dietary SFA, induced apoptosis, oxidative stress, and endoplasmic reticulum (ER) stress in human lymphatic endothelial cells. In a mouse model, a short-term high-SFA diet was used to lower the plasma PUFA/SFA ratio, which worsened tail swelling, oxidative stress, ER stress, and tissue damage following lymphatic injury. Switching to a standard chow diet after surgery prevented these effects. Lymphedema patients also exhibited elevated levels of fatty acid-binding protein 4 (FABP4), a lipid chaperone associated with metabolic stress. FABP4 inhibition reduced stearic acid–induced cell death in vitro and mitigated tissue damage in vivo. These findings suggest a pathogenic role for SFAs and support dietary modulation and FABP4 inhibition as potential therapeutic strategies for lymphedema.

**Keywords:** apoptosis / dietary intervention / endoplasmic reticulum stress / fatty acid-binding protein 4 / oxidative stress.

**Introduction**

Lymphedema is a chronic condition characterized by the accumulation of lymph fluid in the interstitial space, resulting from an insufficient or impaired function of the lymphatic system, which leads to tissue swelling, inflammation, and increased susceptibility to infections (Grada & Phillips, 2017). Secondary lymphedema is caused by an injury to the lymphatic system due to surgery, cancer treatments (radiation and/or chemotherapy), infections, trauma, and/or obesity (Koelmeyer *et al*, 2022; Stout *et al*, 2024). Increasing evidence suggests that secondary lymphedema develops through a multi-step process involving the role of events beyond the initial lymphatic insult in disease progression (Bowman & Rockson, 2024; Sung *et al*, 2022). The underlying reasons why individuals develop secondary lymphedema remain poorly understood.

Several risk factors contribute to the development of secondary lymphedema, including high body mass index (BMI), surgical lymph node removal, and extensive cancer treatments (Garza *et al*, 2017; Jammallo *et al*, 2013; Leray *et al*, 2020). In cancer patients who exhibit these risk factors, the incidence of lymphedema can be as high as 30-50% (Cemal *et al*, 2011; Shen *et al*, 2022). Despite these known associations, the mechanisms linking these risk factors to an increased incidence of lymphedema remain unclear.

The microenvironment of lymphedema is markedly altered, with elevated inflammation mediated by T cells and macrophages, which exacerbates disease progression (Brown *et al*, 2023). Additionally, there is an increase in vascular endothelial growth factor C (VEGF-C) in lymphedema tissue, primarily secreted by macrophages. Despite the presence of VEGF-C, lymphangiogenesis is impaired and dysfunctional (Gousopoulos *et al*, 2017b; Rutkowski *et al*, 2006). Areas of oxidative stress are also evident in the lymphedema microenvironment, and when combined with elevated VEGF-C levels, increased cell death in lymphatic endothelial cells (LECs) further prevents functional lymphangiogenesis (Hossain *et al*, 2024). These pathological conditions underscore the complexity of the lymphedema microenvironment, and the limited therapeutic approaches targeting the lymphedema microenvironment.

Lipotoxicity, a form of metabolic syndrome characterized by the accumulation of lipids in non-adipose tissues, plays a central role in various diseases, including cardiovascular diseases, diabetes, and obesity (Mann *et al*, 2024; Yazici & Sezer, 2017). In a healthy metabolic state, there is a balance between lipid synthesis, oxidation, and cellular uptake. With conditions such as obesity, diabetes, and heart disease, an overabundance of saturated fatty acids (SFAs) contributes to tissue damage through lipotoxicity (Nolan & Larter, 2009; Piccolis *et al*, 2019). Obesity, characterized as a BMI of 30 or higher, is a well-established risk factor for lymphedema, and elevated SFA levels in the blood are commonly observed in obese individuals (Zhou *et al*, 2020). Furthermore, high fat diets (HFDs), which are typically rich in SFAs, have been shown to exacerbate lymphedema severity in animal models. Specifically, mice fed with HFDs display severe tail and hindlimb lymphedema (Blum *et al*, 2014; Khan *et al*, 2022; Savetsky *et al*, 2014). The role lipotoxicity plays in lymphedema progression is unknown.

In this study, we demonstrate that patients with secondary lymphedema exhibit a significantly lower PUFA/SFA ratio in plasma compared to non-lymphedema controls, reflecting an altered fatty acid composition. We also show that stearic acid (SA), a SFA, selectively induces cell death in LECs through endoplasmic reticulum (ER) stress. Furthermore, a high saturated fat diet (HSFD) in mice exacerbated tail lymphedema by prolonging ER stress and promoting LEC death. These findings suggest that changes in the relative proportions of PUFAs and SFAs may contribute to the pathophysiology of lymphedema.

**Results**

**Lymphedema patients have a lower PUFA/SFA ratio than non-lymphedema controls**

Lipids, including fatty acids and lipid mediators, play a critical role in inflammatory responses, tissue remodeling, and cellular homeostasis. To evaluate the impact of circulating lipid levels on lymphedema, we measured the relative levels of fatty acids in 57 patients with secondary lymphedema compared to 22 non-lymphedema controls. Most of these patients (89%) were female and ranged in age from 32 to 88 years. Approximately 67% had a history of breast cancer-related lymphedema, 24% developed lymphedema due to other types of cancer, and 9% had non-cancer-related lymphedema. In addition, 72% of the patients presented with upper extremity lymphedema, the majority of which were cases of breast cancer-related lymphedema. The remaining 28% had lower extremity lymphedema, primarily associated with chronic venous insufficiency, gynecological cancers, prostate cancer, melanoma, and bladder cancer. The demographic characteristics of lymphedema patients and non-lymphedema controls in our study are presented in **Appendix Table S1**. The plasma PUFA/SFA ratio in patients with lymphedema was significantly lower than non-lymphedema controls across different lipid fractions, including phospholipids (PLs; lymphedema: 0.86 vs. non-lymphedema controls: 0.93), triglycerides (TGs; lymphedema: 0.60 vs. non-lymphedema controls: 0.78), and cholesteryl esters (CEs; lymphedema: 4.04 vs. non-lymphedema controls: 4.59) (**Fig. 1, A-C**). There was no significant difference observed in the PUFA/SFA ratio of free fatty acids (FFAs; lymphedema: 0.56 vs. non-lymphedema controls: 0.64) fraction (**Fig. 1D**). The non-lymphedema control group included both healthy individuals and breast cancer patients who did not develop lymphedema. The latter were monitored for up to five years following cancer treatment and remained lymphedema-free throughout the follow-up period. Fatty acid profiles from healthy controls were consistent with previously reported reference values (Larsen *et al*, 2018). Breast cancer controls showed similar levels to healthy controls except for FFAs, where the PUFA/SFA ratio was lower than healthy controls (**Appendix S1**). Furthermore, the low PUFA/SFA ratio in the patients with secondary lymphedema did not correlate with body mass index (BMI) (**Fig. 1E-H**), indicating that the observed fatty acid imbalance is likely not explained by BMI. In contrast, there was a negative correlation between non-lymphedema controls and BMI in the TGs PUFA/SFA ratio (**Appendix S2**). The reduced PUFA/SFA ratio was consistent regardless of whether patients were diagnosed with breast cancer-related lymphedema or non-breast cancer-related lymphedema (**Appendix S1**), and it was notably more pronounced in female patients than males; however, the interpretation of this sex-based difference is limited by the relatively small number of male subjects included in the cohort (**Appendix S3**). Additionally, the lower PUFA/SFA ratio was primarily driven by the higher proportion of palmitic acid (PA, 16:0) and lower levels of the omega-6 PUFA linoleic acid (LA, 18:2n6) in the lymphedema group (**Fig. EV1; Appendix S4**). These findings suggest that an altered fatty acid composition may play a role in the pathophysiology of lymphedema.

**High saturated fat diet prolongs swelling and induces ER stress in a tail lymphedema mouse model**

To better understand the role of a low PUFA/SFA ratio in lymphedema development, we performed dietary interventions in a murine model of surgically induced tail lymphedema. Since most lymphedema patients in our study were female and exhibited a greater reduction in the PUFA/SFA ratio, female C57BL/6J mice were randomly assigned to standard chow diet (CD), HFD, or HSFD (**Appendix S5A**). The composition of the diets used in this study is detailed in **Appendix** **Table S2**. Although statistically significant, a modest increase in body weight (approximately 16%) was observed in the mice from the HFD and HSFD groups compared to the CD group (**Appendix S5B**). This level of weight gain in female C57BL/6 mice is insufficient to induce obesity-related metabolic changes, as this strain and sex are known to be resistant to diet-induced obesity over moderate durations (Casimiro *et al*, 2021).

After 4 weeks on their respective diets, tail lymphedema was surgically induced, and its progression was monitored for an additional 4 weeks. Mice fed with the CD and subjected to surgical lymphatic damage exhibited a progressive increase in tail swelling over a 22-day period compared to sham controls, followed by a reduction in swelling. Mice with lymphedema from both HFD and HSFD groups exhibited an earlier onset of tail swelling compared to the CD-fed lymphedema mice. The HSFD-fed mice showed a significant delay in the reduction in tail swelling, with tail volume remaining 62% higher 28 days post-surgery compared to both the HFD and CD groups **(Fig. 2, A-C**). Only mice fed the HSFD displayed a significantly reduced PUFA/SFA ratio in their plasma compared to the CD group, reflecting the pattern observed in lymphedema patients (**Fig. EV2A**). This was associated with an increased portion of the SFA SA (18:0) and a reduced portion of the omega-6 PUFA linoleic acid (18:2n6) in the mice plasma (**Fig. EV2B**).

To determine whether diets altered microenvironmental stresses in the tail lymphedema model, immunofluorescence staining was performed on tail sections collected 28 days post-lymphatic surgery. We evaluated ER stress markers spliced X-box binding protein 1 (sXBP-1) and C/EBP homologous protein (CHOP) in mice with lymphedema fed the HSFD since lipotoxicity can induces ER stress (Han & Kaufman, 2016; Larsen *et al.*, 2018). This revealed elevated levels of sXBP-1 and CHOP, accompanied by a marked increase in cell death, as indicated by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining. These changes were observed both within the lymphatic vasculature (LYVE-1-positive cells), with sXBP-1, CHOP, and TUNEL levels increasing by 3-fold, 4-fold, and 3-fold, respectively, and in the surrounding perilymphatic tissue, where the same markers increased by 5-fold, 4-fold, and 2-fold, respectively. Although these markers were also elevated in the HFD group (**Fig. EV2, C-I**), the increases were notably less pronounced compared to the HSFD group (**Fig. 2, D-J**). The presence of ER stress and cell death in the lymphedematous tissue of mice fed with the HSFD suggests that a diet high in saturated fat leads to a reduced PUFA/SFA ratio, and prolonged swelling of tail lymphedema in this mouse model.

**Stearic acid selectively induced apoptosis in lymphatic endothelial cells through ER stress and reactive oxygen species**

To investigate the in vitro effects of FFAs on lymphatic and vascular endothelial cells, human dermal lymphatic endothelial cells (HDLECs), human umbilical vein endothelial cells (HUVECs), and human dermal microvascular endothelial cells (HDMECs) were exposed to increasing concentrations of several different fatty acids, and cell death was evaluated using a trypan blue exclusion assay. Increasing concentrations of the SFAs SA and PA resulted in dose-dependent cell death in HDLECs, to a greater extent than HUVECs and HDMECs, indicating that HDLECs are more susceptible to lipotoxicity. Specifically, 24-hour treatment with SA resulted in the following percentages of cell death: Vehicle: 10.2%, 1 µM: 15.5%, 10 µM: 26.8%, 50 µM: 58.0%, and 100 µM: 76.5% (**Fig. 3A**). In comparison, SFA-induced lipotoxicity was lower in HUVECs and HDMECs than in HDLECs, with HDLECs exhibiting a 2-fold increase in cell death with SA and a 1.3-fold increase with PA (**Fig. 3B; Appendix S6**). These findings suggest that LECs are more susceptible to SFA-induced lipotoxicity than vascular endothelial cells. SA also induced dose-dependent cell death in rat mesenteric lymphatic endothelial cells (RMLECs) (**Appendix S6E**). To further confirm that SA induces apoptosis in LECs, we performed flow cytometry analysis with Annexin V/7-AAD staining. Treatment with SA led to a dose-dependent increase in the percentage of apoptotic cells, with 8% cell death observed in the vehicle-treated group, against 15% with 1 µM SA and 25% with 10 µM SA. These findings further underscore the role of SA in inducing apoptosis in HDLECs (**Fig. 3C**).

Corroborating the cell death data, SA selectively inhibited HDLECs growth while exerting minimal effects on HUVECs, as demonstrated by the clonogenic assay. HDLECs exhibited high sensitivity to SA, with 500 nM reducing the number of colonies from 269 to 52 (**Appendix S7, A and B**). In contrast, the same concentration of SA inhibited colony growth in HUVECs from 105 to 75 (**Appendix S7, C and D**). RMLECs required higher SA concentrations to observe significant inhibition of colony formation, with 1 µM reducing it by 1.3-fold and 10 µM reducing it by 37-fold (**Appendix S7, E and F**). The lipid droplet formation detected by the Oil Red O staining was not different between HDLECs and HUVECs following SA treatment, suggesting a similar uptake of SA by these two cell lines (**Appendix S8**).

Given the high sensitivity of HDLECs to SA-induced cell death, we further investigated the mechanisms underlying these lipotoxic effects. SFAs are known to induce lipotoxicity through possible mechanisms involving oxidative stress and ER stress. While these mechanisms have been well-documented in various cell types, their role in LECs remains unknown. To address this, we investigated the involvement of oxidative and ER stress in SA-induced lipotoxicity in LECs. HDLECs were treated with 1 µM and 10 µM SA for 24 hours and subsequently stained with MitoSOX Red and dihydroethidium (DHE) to detect mitochondrial and intracellular reactive oxygen species (ROS) levels by flow cytometry, respectively. SA treatment significantly increased ROS production in HDLECs, with mitochondrial ROS levels, measured by MitoSOX, elevated by 6-fold, and intracellular ROS levels, assessed by DHE staining, elevated by 5-fold (**Fig. 3, D and E; Appendix S9**). In contrast, SA treatment did not significantly alter ROS levels in HDMECs (**Appendix S10**). To confirm the role of oxidative stress, we pretreated HDLECs with the antioxidant α-tocopherol 1 hour before SA exposure. The pretreatment with α-tocopherol significantly reduced SA-induced cell death by 46%, further implicating oxidative stress in SA-mediated lipotoxicity in LECs (**Fig. 3F**). In addition, we examined the involvement of ER stress, a critical pathway in SFA-induced lipotoxicity, by evaluating protein levels of sXBP-1 and CHOP. Western blot analysis revealed a dose-dependent increase in sXBP-1 and CHOP expression following SA treatment (**Appendix S11**), suggesting that ER stress also contributes to SA-induced cell death in LECs. These findings demonstrate that ROS and ER stress contribute to SA-induced cell death in LECs.

**Stearic acid inhibits cell migration and vessel sprouting in lymphatic endothelial cells.**

Following lymphatic injury, lymphangiogenesis is initiated, during which LECs migrate, proliferate, and form new vessels to restore lymphatic function. To assess whether SA impairs this process, we performed a scratch assay to evaluate LEC migration. Under control conditions, HDLECs significantly closed the wound area within 32 hours. However, in the presence of 10 µM SA, wound closure was markedly impaired, indicating a disruption of LEC migratory capacity (**Fig. EV3, A and B**). In contrast, HDMECs were able to significantly reduce the wound area within 48 hours, regardless of the presence of 10 µM SA, indicating that their migratory capacity was not affected (**Fig. EV3, C and D**). To further investigate the impact of SA on lymphangiogenesis, we performed a lymphatic ring assay using thoracic lymphatic trunks excised from mice. Rings were sectioned and embedded in Matrigel supplemented with growth medium. In control conditions, lymphatic vessels exhibited robust cellular proliferation, migration, and new vessel sprouting (red arrows). In contrast, rings treated with 10 µM SA showed no evidence of these lymphangiogenic processes **(Fig. EV3E)**. Together, these findings suggest that SA impairs critical steps in lymphangiogenesis, including endothelial proliferation, migration, and sprouting.

**Oxidative stress potentiates stearic acid-induced apoptotic cell death in lymphatic endothelial cells**

Our previous study demonstrated a significant increase in 8-hydroxy-2′-deoxyguanosine (8-OHdG), a marker of oxidative DNA damage, 12 days after lymphatic ablation in a mouse model of tail lymphedema (Hossain *et al.*, 2024). Building on these findings, we evaluated the impact of dietary interventions on oxidative stress markers in lymphedema. Immunofluorescence analysis demonstrated that 28 days post-lymphatic injury, mice with lymphedema fed the HSFD exhibited significantly higher levels of 8-OHdG, with a Pearson correlation of 0.54 with LYVE-1 positive cells, compared to the CD- (Pearson correlation: 0.21) and the HFD- (Pearson correlation: 0.31) groups (**Fig. 4, A and B; Appendix S12**).

To further investigate the role of oxidative stress in SA-induced lipotoxicity, HDLECs were pre-treated with 1 μM or 10 μM SA for 1 hour, followed by exposure to 300 μM hydrogen peroxide (H₂O₂) for 24 hours. We found that combined SA and H₂O₂ treatment significantly increased cell death by 2-fold when compared to either treatment alone, as indicated by Annexin V/7-AAD assay (**Fig. 4C; Appendix S9A**). Oxidative stress, assessed by flow cytometry via MitoSOX Red and DHE staining, also showed significantly elevated mitochondrial and intracellular ROS levels in cells treated with both SA and H₂O₂ (**Fig. 4, D and E; Appendix S9, B and C**). Western blot analysis was performed to elucidate the mechanisms driving the SA-induced lipotoxicity. HDLECs treated with SA and H₂O₂ showed reduced expression of the anti-apoptotic proteins Bcl-2 and Mcl-1, along with decreased levels of total caspase-3 and total PARP-1, indicating apoptosis activation (**Appendix S13**). These findings indicate that oxidative stress potentiates the SA induced apoptosis in LECs and suggest a mechanistic link between dietary saturated fat, oxidative stress, and lymphatic endothelial dysfunction in lymphedema.

The omega-6 PUFA LA can act as an antioxidant. Given the increased oxidative stress and reduced LA proportions in plasma, we investigated whether LA could mitigate SA-induced lipotoxicity. HDLECs were pretreated with 50mM LA for 30 minutes before a 24-hour exposure to 50mM SA. LA pretreatment significantly protected cells from SA-induced cytotoxicity: while SA alone caused approximately 44% cell death, LA pretreatment reduced cell death to 19% (**Appendix S14**). These results suggest that LA effectively counteracts SA-induced lipotoxic effects in HDLECs.

**Dietary change prevents prolonged tail lymphedema induced by a high saturated fat diet in a mouse model**

To evaluate whether the detrimental effects of HSFD on lymphedema progression could be ameliorated, we transitioned mice from the HSFD to the CD 6 days after surgical lymphedema ablation. This dietary intervention resulted in a significantly less tail swelling, with the HSFD→CD group showing a 30% decrease in tail volume compared to the HSFD group by day 28 post-surgery (**Fig. 5, A and B**). Despite exhibiting a greater increase in tail volume during the early phases of lymphedema progression when compared to mice with lymphedema maintained on CD, the tail volume of mice transitioned from HSFD to CD 6 days after surgery became comparable to that of CD-fed lymphedema mice by 28 days post-surgery. This indicates that transitioning to a CD effectively prevents the sustained tail swelling associated with HSFD consumption.

Furthermore, mice with lymphedema transitioned to the CD after HSFD showed significantly lower levels of oxidative and ER stress. This was evidenced by reduced expression of the oxidative stress marker 8-OHdG, and the ER stress markers sXBP1 and CHOP in both LECs (LYVE-1 positive) and the perilymphatic tissue at 28 days post-surgery. Similarly, cell death, as indicated by TUNEL staining, was also significantly less in both compartments (**Fig. 5, C-I; Appendix S15**). Thus, switching from an HSFD to a CD after the onset of lymphedema effectively prevented tail swelling and reduced key markers of cellular stress, including oxidative stress, ER stress, and cell death.

**FABP4 inhibition attenuates stearic acid-induced lipotoxicity in lymphatic endothelial cells**

To further investigate the mechanism underlying the sensitivity of LECs to lipotoxicity, we investigated whether fatty acid transporting proteins contribute to the observed lipotoxic effects. Fatty acid-binding protein 4 (FABP4) is a key lipid chaperone that regulates intracellular fatty acid trafficking and metabolism. FABP4 levels are elevated in obesity and cancer, and mutations in the gene have been identified in cases of primary lymphedema (Ferrell *et al*, 2008; Zeng *et al*, 2020). We first measured circulating FABP4 levels in plasma samples from patients with lymphedema and non-lymphedema controls. FABP4 levels were 2.8-fold higher in individuals with lymphedema compared to controls (**Fig. 6A, Appendix S16**). These results suggest a potential association between elevated FABP4 levels and the presence of lymphedema.

To explore the role of FABP4 in SFA-induced lipotoxicity in LECs, we performed western blot analysis and found that HDLECs express significantly higher levels of FABP4 protein compared to HUVECs and HDMECs (**Appendix S17A**). To further evaluate the functional significance of FABP4 in SFA-induced lipotoxicity in vitro, we pretreated HDLECs with BMS-309403 (BMS), a selective FABP4 inhibitor, 30 minutes before a 24-hour exposure to SA or PA. A concentration of 5 µM BMS was selected for use, as this was identified as the lowest dose that does not exhibit toxic effects in HDLECs (**Appendix S17B**). FABP4 inhibition significantly reduced cell death induced by both SFAs by approximately 50% (**Fig. 6B**). Furthermore, western blot analysis showed that BMS treatment markedly reduced the protein levels of the ER stress markers sXBP1 and CHOP in SA-treated HDLECs (**Fig. 6C**).

Immunofluorescence staining for FABP4 and the ER marker calreticulin revealed colocalization in HDLECs under control conditions (Pearson’s correlation coefficient = 0.60), indicating ER localization of FABP4 in LECs. However, the 24-hour exposure to SA or FABP4 inhibition did not significantly changed this colocalization pattern (**Fig. 6, D and E**). To validate that the effects of BMS were specifically mediated through FABP4, we performed siRNA-mediated knockdown of FABP4 in HDLECs, which significantly decreased SA-induced cell death (**Fig. 6, F and G**).

To assess lipid accumulation in lymphedematous tissue, we performed Oil Red O staining. Mice fed either a HFD or a HSFD exhibited increased lipid deposition in the lymphedematous region compared to those on the standard chow diet (**Appendix S18**). Pharmacological inhibition of FABP4 with BMS markedly reduced lipid accumulation in HSFD-fed lymphedema mice, reaching levels comparable to those observed in sham-operated or CD-switched animals (**Fig. EV4, A and B**). Immunostaining for FABP4 further revealed an increased number and size of adipocytes in lymphedematous tissue, both of which were significantly reduced following BMS treatment and dietary transition (**Fig. EV4, C-E**). Additionally, HSFD feeding significantly increased circulating FABP4 levels in mice with lymphedema compared to those fed a CD, whereas FABP4 inhibition with BMS attenuated this elevation in HSFD-fed animals (**Fig. EV4F**).

**FABP4 inhibition attenuates tail swelling and oxidative stress in tail lymphedema induced by high saturated fat diet**

Since FABP4 inhibitor blocks SA-induced cell death in HDLECs, we determined whether HFSD alters FABP4 expression. Immunofluorescence staining of tail sections showed increased FABP4 levels in the perilymphatic tissue of HSFD-fed mice with lymphedema compared to both their sham controls and mice in the CD and HFD lymphedema groups. Although a 5-fold increase in FABP4 expression was observed in the HFD-fed lymphedema group compared to the CD group, this increase was less pronounced than the 6.8-fold increase in the HSFD-fed group (**Appendix S19**). These findings suggest that HSFD consumption leads to a robust increase in perilymphatic FABP4 expression in lymphedema, potentially implicating it as a mediator of HSFD-induced lymphatic dysfunction.

To investigate the therapeutic potential of FABP4 inhibition in the HFSD-fed mouse tail lymphedema model, we treated CD- and HSFD-fed mice with the selective FABP4 inhibitor BMS. After 4 weeks of dietary intervention, daily oral BMS treatment was administered by gavage for an additional 4 weeks, starting on the day of surgical lymphedema induction. FABP4 inhibition significantly alleviated tail swelling in HSFD-fed mice, resulting in a 54% reduction in tail volume compared to the vehicle-treated HSFD group. This effect was absent in CD-fed mice, indicating that FABP4 inhibition specifically targets the exacerbating effects of HSFD on lymphedema progression (**Fig. 7, A and B**). BMS treatment attenuated oxidative stress in HSFD-fed mice, as demonstrated by decreased levels of the oxidative stress marker 8-OHdG in both LYVE-1-positive LECs and the surrounding perilymphatic tissue, with reductions of 37% and 44%, respectively (**Appendix S20**). Additionally, BMS treatment mitigated ER stress, as evidenced by reduced expression of the ER stress markers sXBP1 and CHOP in both LYVE-1-positive LECs and perilymphatic tissue, with decreases of 28% and 45% for sXBP1 (**Fig. 7, D and G; Appendix S21**) and 62% and 36% for CHOP (**Fig. 7, E and H; Appendix S21**), respectively. Furthermore, FABP4 inhibition significantly reduced cell death in LECs, as indicated by decreased TUNEL-positive staining in both LYVE-1-positive cells and the surrounding perilymphatic tissue, with reductions of 47% and 21%, respectively (**Fig. 7, F and I; Appendix S21**). The protein levels detected in control mice 28 days post-sham surgery treated with vehicle (PBS) are shown in **Appendix S22**.

During lymphedema, infiltration of immune cells, particularly macrophages and CD4⁺ T cells, is increased in affected tissues. To assess whether FABP4 inhibition or dietary intervention modulates immune cell presence, we performed immunostaining for macrophages (F4/80) and CD4⁺ T cells in lymphedematous tails from mice fed a CD or a HSFD. HSFD-fed mice exhibited a marked increase in perilymphatic immune cell infiltration. F4/80⁺ macrophage area increased by approximately 2.8-fold compared to CD-fed controls, while CD4⁺ T cell area increased by about 2.2-fold. Treatment with the FABP4 inhibitor BMS309403 significantly prevented this immune cell accumulation, bringing macrophage levels down by ~50% and CD4⁺ T cells down by ~40% compared to untreated HSFD mice. These findings indicate that FABP4 inhibition attenuates HSFD-induced immune cell recruitment around lymphatic vessels (**Fig. EV5**).

Collectively, these findings suggest that FABP4 and SA contribute to lymphedema progression by promoting ER stress and oxidative stress, ultimately leading to LECs apoptosis (**Fig. 8**).

**Discussion**

Obesity is a well-established risk factor for lymphedema, with obese individuals undergoing cancer surgery or treatment exhibiting a significantly higher risk of developing this lymphatic disease (Garza *et al.*, 2017; Jammallo *et al.*, 2013; Leray *et al.*, 2020; Shen *et al.*, 2022). In cases of extreme obesity (BMI ≥ 40), lymphatic function is profoundly impaired, further contributing to lymphedema development (Arngrim *et al*, 2013; Greene *et al*, 2015). While some pre-clinical studies have demonstrated an association between HFDs and increased lymphedema severity in both tail and hindlimb lymphedema models (Blum *et al.*, 2014; Khan *et al.*, 2022; Savetsky *et al.*, 2014), others have reported that HFDs do not affect lymphedema in non-obese mice (Choi *et al*, 2023; Gousopoulos *et al*, 2017a). Furthermore, there is currently no evidence indicating that HFD increases the incidence of lymphedema. Our findings provide novel insights by demonstrating that both HFD and HSFD exacerbate tail lymphedema in the early stages of disease progression in mice. The lack of diet-induced obesity in our animal model is attributable to the use of female C57BL/6J mice, which are more resistant to obesity under dietary stress, and the relatively short duration (8 weeks) of dietary intervention (Stapleton *et al*, 2024; Stubbins *et al*, 2012). Notably, only the HSFD delayed the spontaneous resolution of swelling in the mouse tail lymphedema model, indicating the unique impact of dietary SFA content. In addition, our study suggests that the progression of lymphedema may also be exacerbated by alterations in the proportion of PUFAs to SFAs in the lymphatic microenvironment. This is supported by our observation of a lower PUFA/SFA ratio in lymphedema patients, independent of BMI. These findings suggest that metabolic imbalances, particularly those involving dietary fatty acid composition, may play a key role in lymphedema pathogenesis.

LECs require fatty acid β-oxidation (FAO) for lymphangiogenesis, which involves proliferation, migration, and sprouting. FAO supports these processes by generating acetyl-coenzyme A (acetyl-CoA), a critical metabolite necessary for lymphatic differentiation (Wong *et al*, 2018). Alternate sources of acetyl-CoA, such as ketones, can rescue lymphangiogenesis under FAO inhibition and ketogenic diets have demonstrated benefits in pre-clinical lymphedema models. These diets improved lymphatic vessel function and growth, reduced infiltration of anti-lymphangiogenic immune cells, and decreased tail swelling in lymphedema models (Garcia-Caballero *et al*, 2019). Similar benefits have been observed in patients, albeit without accounting for microenvironmental stressors (Lodewijckx *et al*, 2024). However, while fatty acid metabolism is essential for LEC function, not all lipid exposure is beneficial. An excess of SFAs may overwhelm the metabolic capacity of LECs, leading to lipotoxicity. In our study, SFAs such as SA induced apoptosis in LECs and contributed to sustained ER stress and oxidative stress in lymphedematous tissue. Switching from HSFD to a standard chow diet significantly prevented tail swelling, ER stress, and oxidative stress, underscoring the therapeutic potential of dietary modulation. Future studies will investigate the optimal timing of dietary intervention to prevent or mitigate lymphedema progression following lymphatic injury.

Lymphedema microenvironment is also altered by inflammation. Lipid metabolites contribute to inflammation through reduced specialized pro-resolving mediators (SPM) generated by the 15-lipoxygenase (15-LO) and increased leukotriene LTB4 (Singh & Rao, 2019; Zamora *et al*, 2024). Human lipoxygenases catalyze the stereoselective dioxygenation of PUFAs, including arachidonic acid (AA), eicosapentaenoic acid (EPA) and DHA. Treatment with ketoprofen, a nonsteroidal anti-inflammatory drug that inhibits 5-lipoxygenase (5-LO) and cyclooxygenase, effectively reduced inflammation in a murine model of acquired lymphedema (Jiang *et al*, 2018). The effect of HSFD on lipid mediators and the lymphedema immune microenvironment is unknown and will be the focus of future investigations.

SFAs are known to induce lipotoxicity, contributing to metabolic diseases such as insulin resistance and obesity (Nolan & Larter, 2009; Piccolis *et al.*, 2019). In our study, SFAs, specifically SA and PA, induced significant apoptosis in LECs via mechanisms involving ROS generation and ER stress. Interestingly, vascular endothelial cells were less sensitive to these effects, suggesting a distinct susceptibility in LECs. In contrast to SFAs, the omega-6 PUFA LA failed to induce apoptosis. One key difference lies in cellular localization: LA binds to peroxisome proliferator-activated receptor gamma (PPARγ) in the nucleus, while SFAs predominantly localize in the cytosol within lipid droplets or the ER (Muralikumar *et al*, 2017). Additionally, SFAs contribute to β-oxidation in mitochondria, a process linked to increased mitochondrial ROS production following SA treatment (Adeva-Andany *et al*, 2019; Muralikumar *et al.*, 2017), underscoring the central role of mitochondrial dysfunction in SFA-induced lipotoxicity.

Fatty acid binding proteins (FABPs) are essential lipid chaperones that regulate intracellular fatty acid trafficking and metabolism in many different cell types, including LECs. FABP4 binds both SFAs and PUFAs and has been implicated in primary lymphedema, with mutations near its nuclear localization signal suggesting a functional role in disease pathogenesis (Ayers *et al*, 2007; Ferrell *et al.*, 2008). Under oxidative stress, FABP4 preferentially binds PA, potentially altering its function (Furuhashi, 2019). Our results demonstrate that FABP4 inhibition with BMS-309403 significantly reduced SA-induced apoptosis in LECs and ameliorated tail swelling in HSFD-fed mice. We also observed elevated FABP4 levels in plasma from both breast cancer-related and non-breast cancer lymphedema patients, suggesting FABP4 as a potential therapeutic target across diverse patient populations. FABP4 also contributes to cancer proliferation, and FABP4 inhibitors have been demonstrated to block tumor growth in xenograft mice (Zeng *et al.*, 2020). In our study, we found that plasma FABP4 levels in breast cancer-related lymphedema patients remained elevated in individuals who no longer had active cancer, similar to the high circulating FABP4 levels reported in studies evaluating breast cancer patients before initiating cancer treatments (Guaita-Esteruelas *et al*, 2017; Tsakogiannis *et al*, 2021). Surprisingly, the 15 breast cancer patients in our control cohort, who did not develop lymphedema within 5 years of monitoring, exhibited FABP4 levels comparable to those of healthy individuals. Given that FABP4 is typically elevated in breast cancer, this finding raises the possibility that circulating FABP4 could potentially serve as a specific marker for lymphedema after cancer remission. Furthermore, FABP4 inhibitors are in clinical development to treat breast cancer patients. While FABP4 inhibition appears beneficial for obese or diabetic patients, its impact on normal weight individuals remains unclear and could lead to metabolic and inflammatory imbalances. Further studies are needed to better understand these potential side effects. FABP4 plays a key role in fatty acid transport and metabolism in adipocytes and macrophages. Its inhibition could disrupt normal lipid regulation in many different cell types, leading to abnormal fatty acid accumulation, potentially affecting the liver and other metabolic tissues. Inhibiting FABP4 could increase circulating fatty acids, contributing to elevated triglycerides and atherogenic lipoproteins. Nevertheless, given its dual role in promoting cancer proliferation and contributing to lymphedema, FABP4 inhibition represents a compelling therapeutic strategy with the potential to address both cancer-related lymphedema and the metabolic alterations associated with cancer progression.

In conclusion, our study identifies SFAs as a potential driver of microenvironmental stress in lymphedema tissue, leading to ER stress, oxidative stress, and apoptosis. The prolonged tail swelling observed in HSFD-fed mice was prevented by dietary modifications and attenuated by FABP4 inhibition, suggesting these as viable therapeutic strategies. The PUFA/SFA ratio may serve as a potential biomarker for lymphedema risk, guiding dietary interventions and targeted therapies. Future studies will focus on further elucidating the molecular interactions between fatty acids, FABP4, and the lymphatic microenvironment to develop optimized treatments for lymphedema.

**Materials and methods**

**Study approval**

Studies utilizing human samples were approved by the Ethics Committee of the University of Alberta (Pro00115131, 2024\_AB241128). Written, informed consent was obtained from all study subjects prior to participation. Patients were recruited through rehabilitation clinics within Alberta Health Services and the Alberta Cancer Research Biobank. Breast cancer control patients were followed for five years post cancer treatment and did not develop lymphedema during the monitoring period. For animal studies, all experiments and procedures were approved by the Animal Care and Use Committee of the University of Alberta (AUP4047).

**Plasma fatty acid profile**

Blood samples from non-fasted participants (including both non-lymphedema and lymphedema groups) were centrifuged at 1500× g for 15 min at 4 °C, and plasma sample aliquots were stored at −80 °C for subsequent analysis. A modified Folch extraction method (Field *et al*, 1988; Folch *et al*, 1957) was employed to isolate lipids from the plasma samples. Briefly, total lipids were extracted and the lipid classes separated by thin-layer chromatography. Internal standards were added for quantification and identification of individual lipid peaks (Abdelmagid *et al*, 2015). Lipid fractions were methylated (boron trifluoride and hexane at 100 °C) and fatty acids were separated and quantified by automated GLC 7890A (Agilent Technologies) on a CP-Sil 88 column (100 m × 0.25 mm; Agilent) (Cruz-Hernandez *et al*, 2013). Fatty acids were expressed as the relative percentage of total fatty acid content.

**Mice**

Female C57BL/6J mice (6 weeks old) were obtained from Charles River Laboratories and housed at the Health Sciences Laboratory Animal Services (HSLAS) facility at the University of Alberta. Mice were maintained in a temperature- and humidity-controlled environment with a 12/12-hour reverse light-dark cycle. After a two-week acclimation period on a standard CD (5053, PicoLab Rodent Diet 20, LabDiet), mice were randomly assigned to one of three dietary groups: CD, HFD (D12492, Research Diets Inc) or HSFD (D12113001, Research Diets Inc). Both the HFD and HSFD provided 60% of their energy from fat. However, the primary fat source of the HFD consisted of lard, while the HSFD was predominantly composed of cocoa butter. The detailed composition of each diet is provided in Supplementary Table 2. Mice were fed their respective diets for four weeks before the surgical intervention and remained on these diets for an additional four weeks post-surgery. To determine the effects of pharmacological inhibition of FABP4, either the FABP4 inhibitor BMS-309403 (15 mg·kg⁻¹·day⁻¹; HY-101903A, MedChemExpress, NJ, USA)) or vehicle (phosphate-buffered saline, PBS) was administered chronically by daily oral gavage for 4 weeks starting on the day of the lymphatic surgery.

**Tail lymphedema model**

Acquired lymphedema was surgically induced in mice by ablating the lymphatic trunks in the tail. Mice were anesthetized with 2-3% isoflurane and maintained on a heating pad to keep their body temperature at 36.5-37.5°C. A 3-mm circumferential incision was made 2 cm from the base of the tail, and the lymphatic trunks were ablated using microsurgical scissors under a surgical microscope. Only the skin was incised in the sham surgery group, leaving the primary collecting lymphatics intact. Mice showing signs of tail necrosis or infection post-surgery were excluded. Tail circumference was measured every other day using a digital caliper at 5-mm intervals starting from the surgical site. The tail volume was calculated using the truncated cone equation. Mice were euthanized 28 days after surgery, and tails, along with cardiac blood, were collected for further analysis.

**Hematoxylin and eosin staining**

To evaluate tissue morphology in the context of lymphedema, tail tissues were fixed overnight in 10% neutral buffered formalin (Fisher Scientific, Ottawa, ON, Canada), decalcified using 10% ethylenediaminetetraacetic acid (EDTA; Sigma-Aldrich, St. Louis, MO, USA), and embedded in paraffin. H&E staining was performed on 5 µm sections according to standard histological protocols. Stained slides were examined using a ZEISS Axioplan 2 (ZEISS, Oberkochen, Germany) light microscope.

**Immunofluorescence staining**

Paraffin-embedded tail sections (5 µm) were rehydrated and subjected to heat-mediated antigen retrieval using IHC antigen retrieval solution (Thermo Fisher Scientific). Sections were incubated overnight at 4 °C with primary antibodies against the following markers: LYVE-1 (PA1-16636, Thermo Fisher Scientific), 8-OHdG (ab48508, Abcam, Cambridge, UK), sXBP-1 (40435, Cell Signaling Technology, Danvers, MA, USA), CHOP (2895, Cell Signaling Technology), F4/80 (MA1-91124, Thermo Fisher Scientific), CD4 (14-0041-82, Thermo Fisher Scientific), and/or FABP4 (MA5-49201, Thermo Fisher Scientific). Secondary antibodies were labeled with the fluorochromes Alexa Fluor 488, Alexa Fluor 555, or Alexa Fluor 647 (Thermo Fisher Scientific). Nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich). Immunofluorescence (IF) slides were imaged using a ZEISS Axio Imager 2 (ZEISS, Oberkochen, Germany) fluorescence microscope. Fluorescence image acquisition was performed with fixed acquisition settings across all experimental groups. Exposure time and laser power for each fluorophore channel were initially calibrated using samples with the highest expected fluorescence intensity. These standardized settings were applied to all samples in each experiment to ensure analytical consistency and to avoid post-acquisition bias.

Image analysis was performed using Fiji software version 1.54f (National Institutes of Health, Bethesda, MD, USA). A minimum of five high-powered fields per animal were analyzed. For fluorescence analysis, the percentage of positive area was quantified relative to the total DAPI-stained nuclear area. LYVE-1⁺ lymphatic vessels were first identified morphologically and outlined manually using the polygon selection tool in Fiji to generate vessel-specific regions of interest (ROIs). A concentric perilymphatic area extending 100 µm from each vessel was created using the “Enlarge” function. Within this defined zone, binary masks were generated for each marker channel after consistent thresholding. The “Measure” function in Fiji was used to calculate the total positive area, and values were expressed as a percentage of the total nuclear (DAPI) area in the corresponding ROI. This approach allowed normalization for cell density and tissue section variability. To evaluate marker expression within lymphatic endothelial cells (LECs), colocalization analysis was performed within the LYVE-1⁺ vessel ROIs. Colocalization of each marker with LYVE-1 was assessed using the “Coloc 2” plugin, which computes Pearson’s correlation coefficient. Channels were aligned and background-subtracted before analysis. Nuclear colocalization was further validated by confirming overlap with DAPI staining. Given that LYVE-1 can also label subsets of macrophages, additional morphological features such as vessel shape and lumen presence were used to distinguish true lymphatic structures. In select experiments, F4/80 was used as a secondary macrophage marker to validate lymphatic endothelial identity.

Adipocyte size and number were quantified in sections stained for FABP4, a cytoplasmic marker of mature adipocytes. Adipocytes were identified based on FABP4⁺ staining, large cytoplasmic area, and the presence of a peripherally displaced DAPI⁺ nucleus. Mean adipocyte area was calculated per field. Adipocyte number was expressed as the total number of FABP4⁺ adipocytes per high-powered field. At least five fields per animal were analyzed.

Cells were fixed with 4% paraformaldehyde (sc-281692, Santa Cruz Biotechnology) in PBS for 15 minutes at room temperature. Following fixation, cells were washed and incubated with primary antibodies against FABP4 and calreticulin (MA5-51367, Thermo Fisher Scientific). After overnight incubation with primary antibodies, appropriate species-specific secondary antibodies conjugated to Alexa Fluor 488 or Alexa Fluor 647 (Thermo Fisher Scientific) were applied. Nuclei were counterstained with DAPI. Fluorescent images were captured using a ZEISS Axio Imager 2 microscope. For each experimental condition, at least four randomly selected, non-overlapping fields were acquired per replicate, with three independent biological replicates analyzed. Colocalization between calreticulin and FABP4 was assessed by calculating Pearson correlation coefficients using the Coloc2 plugin in Fiji. Before analysis, fluorescence channels were aligned, and background signals were subtracted to minimize artifacts and ensure robust quantification.

**TUNEL Assay**

To determine the amount of cell death in lymphedema tissue, the TUNEL method was performed to label apoptotic DNA fragmentation in the tail sections. The TUNEL assay was carried out with the Click-iTTM Plus TUNEL Apoptosis Assay Kit (C10618, Thermo Fisher Scientific) combined with Anti-LYVE-1, according to the manufacturer’s instruction. The images of TUNEL-positive cells were captured using a ZEISS Axio Imager 2 fluorescent microscope and subsequently quantified using Fiji software.

**Cell culture and treatments**

Three different primary endothelial cell lines were utilized in this study: Human Dermal Lymphatic Endothelial Cells (HDLECs; C-12217, PromoCell, Heidelberg, Germany), derived from juvenile foreskin (donor sex not specified); Human Umbilical Vein Endothelial Cells (HUVECs; C0035C, Thermo Fisher Scientific), isolated from a single male newborn donor (≤14 days old); and Rat Mesenteric Lymphatic Endothelial Cells (RMLECs), generously provided by Dr. Pierre-Yves von der Weid (University of Calgary, Calgary, Canada). All primary cell lines were cultured on tissue culture plates coated with 0.2% gelatin (Sigma-Aldrich) and maintained in Endothelial Cell Growth Medium-2 (ECGM-2; C-22121, PromoCell) supplemented with the manufacturer’s recommended additives, including 5% fetal bovine serum (FBS). Cells were incubated at 37 °C in a humidified atmosphere containing 5% CO₂ and used for experiments between passages 5 and 8. Additionally, the immortalized Human Dermal Microvascular Endothelial Cells (HDMECs; CRL-3243, ATCC, Manassas, VA, USA), derived from the foreskin of a male infant (<1 month old), were cultured in MCDB-131 medium supplemented with 5% FBS (12483-012, Thermo Fisher Scientific), 10 ng/mL human epidermal growth factor (hEGF; E9644, Sigma-Aldrich), 1 µg/mL hydrocortisone (H0396, Sigma-Aldrich), and 10 mM L-glutamine (25030081, Gibco). HDMECs were also seeded on 0.2% gelatin-coated plates and maintained at 37 °C with 5% CO₂ in a humidified incubator. Prior to treatment, all cell lines were incubated overnight in medium containing 1% FBS. Drug treatments were performed when cultures reached approximately 70–80% confluency, corresponding to a subconfluent state. Representative phase-contrast images of cell morphology at the time of treatment are provided in **Appendix Figure S23A**. All in vitro experiments were performed in at least three independent replicates.

Stock solutions of the saturated fatty acids stearic acid (SA; 85679, Sigma-Aldrich) and palmitic acid (PA; AC129702500, Fisher Scientific, Ottawa, ON, Canada) were prepared by conjugation to fatty acid–free bovine serum albumin (BSA) (A3803, Sigma-Aldrich) to enhance solubility and cellular bioavailability in aqueous media. Fatty acids were first dissolved in a minimal volume of 0.1 M NaOH, heated to 70 °C until fully solubilized, and then added to prewarmed (55 °C) 10% BSA solution. The mixture was incubated at 55 °C for 30 minutes with constant stirring to facilitate complete conjugation. Cells were treated with stearic acid at final concentrations ranging from 1 to 100 µM, and with palmitic acid at concentrations ranging from 1 to 500 µM, for 24 or 48 hours. The polyunsaturated fatty acid linoleic acid (LA; AC215040250, Fisher Scientific) was handled and stored under a nitrogen atmosphere in amber glass vials to prevent oxidation. LA was added dropwise to prewarmed BSA solution with gentle stirring under nitrogen until fully incorporated. All fatty acid–BSA complexes were prepared at a final molar ratio of 4:1, a condition optimized to reflect physiological relevance and ensure consistent delivery across experimental conditions. Standardized conjugation protocols were used throughout the study to ensure reproducibility across batches and fatty acid species.

Stock solutions of the antioxidant α-tocopherol (258024, Sigma-Aldrich) were prepared in ethanol, while the FABP4 inhibitor BMS-309403 (5258, Tocris Bioscience, Bristol, UK) was dissolved in DMSO (D2650, Sigma-Aldrich). Hydrogen peroxide (H₂O₂) (H325-500, Fisher Scientific) was diluted in sterile water and used as a pre-treatment to mimic oxidative stress conditions. Working dilutions of all compounds were freshly prepared in cell culture media immediately prior to use. Pre-treatments with α-tocopherol (200 µg/mL) and H₂O₂ (300 µM) were administered 1 hour before saturated fatty acid exposure, while LA (50 µM) and BMS-309403 (5 µM) were added 30 minutes prior to treatment.

**Cell viability assays**

Cell viability was assessed using multiple assays to evaluate different aspects of cell death and survival. The trypan blue exclusion assay was used to measure cell viability by staining cells with 0.04% trypan blue (T8154, Sigma-Aldrich). After treatments, cells and cell culture media containing dead floating cells were collected, resuspended in PBS, and stained with trypan blue at a 1:1 ratio. Viable cells remained unstained, while non-viable cells were stained blue. Live and dead cells were counted using a hemocytometer, and total cell death was calculated as total cell death (%) = dead cells/(live + dead cells) × 100. Representative images of stained cells acquired during the assay are shown in **Appendix S23B**. The annexin V/7-AAD assay quantified apoptosis and cell death by staining cells with annexin V-FITC and 7-AAD (BD Biosciences, San Jose, CA, USA). Apoptotic cells were identified by annexin V positivity, and data were acquired using the Attune NxT flow cytometer (Life Technologies, Thermo Fisher Scientific). A total of 10,000 events were analyzed using FlowJo software (version 10.10, Tree Star Inc.). Lastly, the clonogenic assay was performed to evaluate long-term cell survival. Cells were seeded at low density, cultured for 7–14 days to allow colony formation, then fixed with 4% paraformaldehyde, stained with 0.5% crystal violet (C6158, Sigma-Aldrich), and manually counted. Colonies were defined as clusters containing ≥50 cells.

**Oil Red O staining**

Lipid accumulation was assessed using Oil Red O (ORO) staining. For cultured cells, after treatment, cells were washed with PBS, fixed in 4% paraformaldehyde for 15 minutes at room temperature, air-dried, and stained with freshly filtered ORO solution (AAA1298922, Fisher Scientific) for 30 minutes, following the manufacturer’s protocol. Excess stain was removed with 60% isopropanol, and lipid droplets were visualized using a bright-field microscope. For mouse tail tissue, 10 µm cryosections were air-dried at room temperature, fixed in 10% neutral buffered formalin for 10 minutes, and stained with freshly filtered ORO solution for 30 minutes. Slides were washed in 60% isopropanol (439207, Sigma-Aldrich), rinsed with distilled water, and counterstained with hematoxylin. All slides were mounted using aqueous medium and imaged under a light microscope using standardized settings to enable qualitative and semi-quantitative comparisons.

**ROS detection**

After treatment, cells were harvested with the culture media, resuspended in PBS, and stained with 3.2 µM dihydroethidium (DHE, D11347, Thermo Fisher Scientific) for 30 minutes at 37°C to assess total ROS levels. For detection of mitochondrial superoxide, cells were stained with 1 µM MitoSox Red (M36008, Thermo Fisher Scientific) for 30 minutes at 37°C. ROS levels were quantified using an Attune NxT flow cytometer, and data were analyzed using FlowJo software (version 10.10). A total of 10,000 events were collected per sample, and ROS levels were measured based on fluorescence intensity.

**Western Blotting**

To assess protein expression, protein lysates were prepared using NP40 lysis buffer supplemented with protease and phosphatase inhibitors (78440, Thermo Fisher Scientific). Protein concentrations were determined using the Pierce BCA Protein Assay Kit (23225, Thermo Fisher Scientific), and measurements were taken with a FLUOstar Omega multi-plate reader (BMG Labtech, Ortenberg, Germany). Equal amounts of 20–30 µg of protein were loaded onto a Tris-glycine SDS-PAGE gel and separated by electrophoresis. Proteins were then transferred to nitrocellulose membranes using the Trans-Blot Turbo (Bio-Rad, Hercules, USA). Membranes were incubated overnight at 4°C with primary antibodies diluted in 0.1% TBS-T, followed by a 1-hour incubation with HRP-conjugated secondary antibodies. Protein bands were detected using Clarity Western ECL substrate (170-5060, Bio-Rad) and imaged with the UVP ChemStudio gel imaging system (Analytikjena, Upland, CA, USA). Quantification of protein expression was performed using Fiji software version 1.54f (National Institutes of Health, Bethesda, MD, USA). The following primary antibodies were used: Anti-sXBP-1 (40435, Cell Signaling Technology), Anti-CHOP (2895, Cell Signaling Technology), Anti-Mcl-1 (94296, Cell Signaling Technology, Danvers, MA, USA), Anti-Bcl-2 (15071, Cell Signaling Technology), Anti-Caspase 3 (9662, Cell Signaling Technology), Anti-PARP1 (9542, Cell Signaling Technology), Anti-FABP4 (MA5-49201, Thermo Fisher Scientific), Anti-FABP5 (PA5-92929, Thermo Fisher Scientific), Anti-GAPDH (AM4300, Thermo Fisher Scientific), and Anti-alpha-Tubulin (2125, Cell Signaling Technology). Secondary antibodies of HRP goat anti-mouse IgG (926-80010) and HRP goat anti-rabbit IgG (926-80011) were purchased from LI-COR Biotechnology (Lincoln, NE, USA).

**In vitro scratch assay**

Endothelial cell migration was evaluated using a high-throughput scratch wound assay in 96-well plates. HDLECs and HDMECs were seeded to confluency and uniformly scratched using the AutoScratch Wound Making Tool (Agilent Technologies). Detached cells were removed by gentle washing with PBS, and fresh culture medium containing either vehicle or 10 µM SA was added. Plates were transferred to the BioSpa 8 Automated Incubator (Agilent Technologies) integrated with the Cytation 10 Cell Imaging Reader (Agilent Technologies), and high-contrast brightfield images were acquired every 4 hours over 48 hours using BioSpa OnDemand Software v1.04. Wound area was quantified using Fiji software with the Wound Healing Size Tool plugin, which enabled automated detection and measurement of the wound area across time points.

**Lymphatic Ring Assay**

Lymphatic sprouting was assessed using an ex vivo ring assay adapted from a previously described protocol (Bruyere *et al*, 2008). Briefly, mouse lymphatic thoracic trunks were carefully dissected, cleaned of surrounding adipose tissue, and cut into ~1 mm segments under a stereomicroscope. Type I collagen (1 mg/mL) was prepared in DMEM, and the pH was adjusted to 7.4. The collagen solution was dispensed into 96-well plates and allowed to polymerize at 37 °C. Lymphatic thoracic duct segments were embedded in the polymerized collagen and overlaid with MCDB-131 medium supplemented with 2.5% FBS. Cultures were maintained at 37 °C in a humidified 5% CO₂ incubator for 48 hours before treatment with either vehicle or 10 µM SA. Lymphatic sprouting was monitored by phase-contrast microscopy between days 7 and 14.

**FABP4 ELISA**

Plasma levels of FABP4 were quantified using species-specific ELISA kits following the manufacturers’ protocols. The FABP4/A-FABP Human ELISA Kit (EH177RB, Thermo Fisher Scientific) was used for human samples, while the Mouse FABP4/A-FABP ELISA Kit (NBP2-82410, Novus Biologicals) was used for mouse samples. Both assays utilize a quantitative sandwich enzyme immunoassay format to ensure specific and sensitive detection of FABP4.

**siRNA-mediated FABP4 knockdown**

FABP4 knockdown in HDLECs was performed using siRNA transfection. HDLECs were seeded onto 0.2% gelatin-coated plates in ECMV2 medium supplemented with 5% FBS and allowed to adhere overnight. On the following day, cells were transfected with 10 nM FABP4-targeting siRNA (Silencer Select Pre-Designed siRNA, s4964, Invitrogen) or negative control siRNA (Silencer Select Negative Control, 4390843, Invitrogen) using Lipofectamine RNAiMAX (Invitrogen, 13778075) in Opti-MEM (Gibco, 31985062), following the manufacturer’s protocol. Briefly, siRNA and transfection reagent were pre-incubated in Opti-MEM for 15–20 minutes at room temperature before being added to cells cultured in serum-free ECMV2 medium. Cells were incubated with the transfection mix for 18 hours. Following transfection, cells were washed and cultured in ECMV2 medium supplemented with 5% FBS for 24 hours. The medium was then replaced with 1% FBS for an additional overnight incubation. Fatty acid treatment was carried out the next day by exposing cells to 10 µM SA or vehicle control for 16 hours. Cells were harvested 96 hours post-transfection, at which point FABP4 protein levels were significantly reduced, and processed for viability assays and western blot analysis.

**Statistics analysis**

GraphPad Prism version 10.2.3. was used for statistical analysis. Pearson correlation analysis was used to determine the correlations between human plasma analytes and the immunostaining colocalizations. The significance was determined by unpaired *t*-tests. For the mouse data, differences between groups were identified using two-way ANOVA followed by Šídák’s post hoc test. For the in vitro data, statistical significance was determined using one-way ANOVA followed Tukey’s post hoc test or an unpaired *t*-test. Data are presented as mean ± standard error of the mean (SEM) and P values lower than 0.05 were considered statistically significant.

**Acknowledgments**

This research was supported by the University Hospital Foundation research grant (RES0056514). We are profoundly grateful to Dianne and Irving Kipnes for their extraordinary generosity and visionary leadership in supporting the University Hospital Foundation. Dianne Kipnes, who sadly passed away recently, dedicated her life to advancing learning, higher education, and innovative initiatives in healthcare and beyond. Her contributions will leave a legacy, and we are deeply honored to recognize her role in supporting this work and dedicate this paper in her memory.

We also extend our gratitude to Dr. Pierre-Yves von der Weid (University of Calgary) for providing the RMLECs and his valuable scientific advice. Additionally, we acknowledge Dr. David Eisenstat for his critical review of the manuscript. We also thank the University of Alberta's Flow Cytometry Core and Imaging Core facilities for their technical support.

**Author contributions**

The study was designed by KPG, CJF, and SBG. Experiments were conducted by KPG, JK, EL, XY, SG, and JM. KPG, JK, EL, SG, and JM analyzed data. NP identified eligible human subjects, obtained informed consent, and processed blood samples. KPG and SBG wrote the manuscript. All authors read and approved the final manuscript.

**Disclosure and competing interests statement**

The authors declare no competing interests.

**Data Availability**

All data supporting the findings of the main figures and Expanded View figures are available in the accompanying source data files.

**The paper explained**

**Problem**

Secondary lymphedema is a chronic and debilitating condition that impairs the lymphatic system, causing swelling, pain, recurrent infections, and reduced quality of life. While commonly triggered by cancer treatments, surgery, infections, or obesity, the role of dietary components, particularly saturated fatty acids (SFAs), in its progression remains poorly understood. Lipotoxicity, a detrimental consequence of excess SFAs, may contribute to lymphatic dysfunction, yet its underlying mechanisms and therapeutic interventions are not well-defined.

**Results**

This study reveals that patients with secondary lymphedema have a reduced polyunsaturated fatty acid (PUFA) to SFA ratio, independent of body mass index. In lymphatic endothelial cells, stearic acid, a common SFA, triggers cell death, oxidative stress, and endoplasmic reticulum stress. Using a mouse model, a high SFA diet was shown to exacerbate lymphedema-related swelling and tissue damage after surgery, even in the absence of obesity. Importantly, transitioning to a standard diet post-surgery alleviated these effects. Elevated levels of fatty acid-binding protein 4 (FABP4) were also detected in lymphedema patients. Inhibiting FABP4 reduced stearic acid-induced damage in cells and mitigated lymphedema-related swelling and tissue injury in mice.

**Impact**

These findings highlight the detrimental role of SFAs in lymphedema progression through lipotoxicity, providing critical insights into its pathophysiology. This research suggests that dietary interventions to reduce SFAs and therapeutic targeting of FABP4 may offer new strategies to manage or prevent lymphedema, improving outcomes and quality of life for affected patients.

**References**

Abdelmagid SA, Clarke SE, Nielsen DE, Badawi A, El-Sohemy A, Mutch DM, Ma DW (2015) Comprehensive profiling of plasma fatty acid concentrations in young healthy Canadian adults. *PLoS One* 10: e0116195

Adeva-Andany MM, Carneiro-Freire N, Seco-Filgueira M, Fernandez-Fernandez C, Mourino-Bayolo D (2019) Mitochondrial beta-oxidation of saturated fatty acids in humans. *Mitochondrion* 46: 73-90

Arngrim N, Simonsen L, Holst JJ, Bulow J (2013) Reduced adipose tissue lymphatic drainage of macromolecules in obese subjects: a possible link between obesity and local tissue inflammation? *Int J Obes (Lond)* 37: 748-750

Ayers SD, Nedrow KL, Gillilan RE, Noy N (2007) Continuous nucleocytoplasmic shuttling underlies transcriptional activation of PPARgamma by FABP4. *Biochemistry* 46: 6744-6752

Blum KS, Karaman S, Proulx ST, Ochsenbein AM, Luciani P, Leroux JC, Wolfrum C, Detmar M (2014) Chronic high-fat diet impairs collecting lymphatic vessel function in mice. *PLoS One* 9: e94713

Bowman C, Rockson SG (2024) The Role of Inflammation in Lymphedema: A Narrative Review of Pathogenesis and Opportunities for Therapeutic Intervention. *Int J Mol Sci* 25

Brown S, Dayan JH, Kataru RP, Mehrara BJ (2023) The Vicious Circle of Stasis, Inflammation, and Fibrosis in Lymphedema. *Plast Reconstr Surg* 151: 330e-341e

Bruyere F, Melen-Lamalle L, Blacher S, Roland G, Thiry M, Moons L, Frankenne F, Carmeliet P, Alitalo K, Libert C *et al* (2008) Modeling lymphangiogenesis in a three-dimensional culture system. *Nat Methods* 5: 431-437

Casimiro I, Stull ND, Tersey SA, Mirmira RG (2021) Phenotypic sexual dimorphism in response to dietary fat manipulation in C57BL/6J mice. *J Diabetes Complications* 35: 107795

Cemal Y, Pusic A, Mehrara BJ (2011) Preventative measures for lymphedema: separating fact from fiction. *J Am Coll Surg* 213: 543-551

Choi J, Kim J, Kim J, Jeong W, Jo T, Lee HW, Park YS, Park SW (2023) A High-Fat Diet in the Absence of Obesity Increases Lymphangiogenesis by Inducing VEGF-C in a Murine Lymphedema Model. *Plast Reconstr Surg* 152: 87-96

Cruz-Hernandez C, Goeuriot S, Giuffrida F, Thakkar SK, Destaillats F (2013) Direct quantification of fatty acids in human milk by gas chromatography. *J Chromatogr A* 1284: 174-179

Ferrell RE, Kimak MA, Lawrence EC, Finegold DN (2008) Candidate gene analysis in primary lymphedema. *Lymphat Res Biol* 6: 69-76

Field CJ, Ryan EA, Thomson AB, Clandinin MT (1988) Dietary fat and the diabetic state alter insulin binding and the fatty acyl composition of the adipocyte plasma membrane. *Biochem J* 253: 417-424

Folch J, Lees M, Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipides from animal tissues. *J Biol Chem* 226: 497-509

Furuhashi M (2019) Fatty Acid-Binding Protein 4 in Cardiovascular and Metabolic Diseases. *J Atheroscler Thromb* 26: 216-232

Garcia-Caballero M, Zecchin A, Souffreau J, Truong AK, Teuwen LA, Vermaelen W, Martin-Perez R, de Zeeuw P, Bouche A, Vinckier S *et al* (2019) Role and therapeutic potential of dietary ketone bodies in lymph vessel growth. *Nat Metab* 1: 666-675

Garza R, 3rd, Skoracki R, Hock K, Povoski SP (2017) A comprehensive overview on the surgical management of secondary lymphedema of the upper and lower extremities related to prior oncologic therapies. *BMC Cancer* 17: 468

Gousopoulos E, Karaman S, Proulx ST, Leu K, Buschle D, Detmar M (2017a) High-Fat Diet in the Absence of Obesity Does Not Aggravate Surgically Induced Lymphoedema in Mice. *Eur Surg Res* 58: 180-192

Gousopoulos E, Proulx ST, Bachmann SB, Dieterich LC, Scholl J, Karaman S, Bianchi R, Detmar M (2017b) An Important Role of VEGF-C in Promoting Lymphedema Development. *J Invest Dermatol* 137: 1995-2004

Grada AA, Phillips TJ (2017) Lymphedema: Pathophysiology and clinical manifestations. *J Am Acad Dermatol* 77: 1009-1020

Greene AK, Grant FD, Maclellan RA (2015) Obesity-induced Lymphedema Nonreversible following Massive Weight Loss. *Plast Reconstr Surg Glob Open* 3: e426

Guaita-Esteruelas S, Saavedra-Garcia P, Bosquet A, Borras J, Girona J, Amiliano K, Rodriguez-Balada M, Heras M, Masana L, Guma J (2017) Adipose-Derived Fatty Acid-Binding Proteins Plasma Concentrations Are Increased in Breast Cancer Patients. *Oncologist* 22: 1309-1315

Han J, Kaufman RJ (2016) The role of ER stress in lipid metabolism and lipotoxicity. *J Lipid Res* 57: 1329-1338

Hossain L, Gomes KP, Yang X, Liu E, Du Toit J, von der Weid PY, Gibson SB (2024) Vascular Endothelial Growth Factor C (VEGF-C) Sensitizes Lymphatic Endothelial Cells to Oxidative-Stress-Induced Apoptosis through DNA Damage and Mitochondrial Dysfunction: Implications for Lymphedema. *Int J Mol Sci* 25

Jammallo LS, Miller CL, Singer M, Horick NK, Skolny MN, Specht MC, O'Toole J, Taghian AG (2013) Impact of body mass index and weight fluctuation on lymphedema risk in patients treated for breast cancer. *Breast Cancer Res Treat* 142: 59-67

Jiang X, Nicolls MR, Tian W, Rockson SG (2018) Lymphatic Dysfunction, Leukotrienes, and Lymphedema. *Annu Rev Physiol* 80: 49-70

Khan N, Huayllani MT, Lu X, Boczar D, Cinotto G, Avila FR, Guliyeva G, Forte AJ (2022) Effects of diet-induced obesity in the development of lymphedema in the animal model: A literature review. *Obes Res Clin Pract* 16: 197-205

Koelmeyer LA, Gaitatzis K, Dietrich MS, Shah CS, Boyages J, McLaughlin SA, Taback B, Stolldorf DP, Elder E, Hughes TM *et al* (2022) Risk factors for breast cancer-related lymphedema in patients undergoing 3 years of prospective surveillance with intervention. *Cancer* 128: 3408-3415

Larsen SV, Holven KB, Ottestad I, Dagsland KN, Myhrstad MCW, Ulven SM (2018) Plasma fatty acid levels and gene expression related to lipid metabolism in peripheral blood mononuclear cells: a cross-sectional study in healthy subjects. *Genes Nutr* 13: 9

Leray H, Malloizel-Delaunay J, Lusque A, Chantalat E, Bouglon L, Chollet C, Chaput B, Garmy-Susini B, Yannoutsos A, Vaysse C (2020) Body Mass Index as a Major Risk Factor for Severe Breast Cancer-Related Lymphedema. *Lymphat Res Biol* 18: 510-516

Lodewijckx I, Matthys C, Verheijen J, Verscuren R, Devoogdt N, Van der Schueren B, Goffin K, Fourneau I, Thomis S (2024) Potential therapeutic effect of a ketogenic diet for the treatment of lymphoedema: Results of an exploratory study. *J Hum Nutr Diet* 37: 885-891

Mann V, Sundaresan A, Shishodia S (2024) Overnutrition and Lipotoxicity: Impaired Efferocytosis and Chronic Inflammation as Precursors to Multifaceted Disease Pathogenesis. *Biology (Basel)* 13

Muralikumar S, Vetrivel U, Narayanasamy A, U ND (2017) Probing the intermolecular interactions of PPARgamma-LBD with polyunsaturated fatty acids and their anti-inflammatory metabolites to infer most potential binding moieties. *Lipids Health Dis* 16: 17

Nolan CJ, Larter CZ (2009) Lipotoxicity: why do saturated fatty acids cause and monounsaturates protect against it? *J Gastroenterol Hepatol* 24: 703-706

Piccolis M, Bond LM, Kampmann M, Pulimeno P, Chitraju C, Jayson CBK, Vaites LP, Boland S, Lai ZW, Gabriel KR *et al* (2019) Probing the Global Cellular Responses to Lipotoxicity Caused by Saturated Fatty Acids. *Mol Cell* 74: 32-44 e38

Rutkowski JM, Moya M, Johannes J, Goldman J, Swartz MA (2006) Secondary lymphedema in the mouse tail: Lymphatic hyperplasia, VEGF-C upregulation, and the protective role of MMP-9. *Microvasc Res* 72: 161-171

Savetsky IL, Torrisi JS, Cuzzone DA, Ghanta S, Albano NJ, Gardenier JC, Joseph WJ, Mehrara BJ (2014) Obesity increases inflammation and impairs lymphatic function in a mouse model of lymphedema. *Am J Physiol Heart Circ Physiol* 307: H165-172

Shen A, Lu Q, Fu X, Wei X, Zhang L, Bian J, Qiang W, Pang D (2022) Risk factors of unilateral breast cancer-related lymphedema: an updated systematic review and meta-analysis of 84 cohort studies. *Support Care Cancer* 31: 18

Singh NK, Rao GN (2019) Emerging role of 12/15-Lipoxygenase (ALOX15) in human pathologies. *Prog Lipid Res* 73: 28-45

Stapleton S, Welch G, DiBerardo L, Freeman LR (2024) Sex differences in a mouse model of diet-induced obesity: the role of the gut microbiome. *Biol Sex Differ* 15: 5

Stout NL, Ibrahim M, Armer J, Vargo M, Rodrick J, Nourse J, McKeown B, Griffin JC, Aldrich MB (2024) Consensus statement on non-cancer-related risk factors for development of secondary lymphedema. *Med Oncol* 41: 284

Stubbins RE, Holcomb VB, Hong J, Nunez NP (2012) Estrogen modulates abdominal adiposity and protects female mice from obesity and impaired glucose tolerance. *Eur J Nutr* 51: 861-870

Sung C, Wang S, Hsu J, Yu R, Wong AK (2022) Current Understanding of Pathological Mechanisms of Lymphedema. *Adv Wound Care (New Rochelle)* 11: 361-373

Tsakogiannis D, Kalogera E, Zagouri F, Zografos E, Balalis D, Bletsa G (2021) Determination of FABP4, RBP4 and the MMP-9/NGAL complex in the serum of women with breast cancer. *Oncol Lett* 21: 85

Wong BW, Zecchin A, Garcia-Caballero M, Carmeliet P (2018) Emerging Concepts in Organ-Specific Lymphatic Vessels and Metabolic Regulation of Lymphatic Development. *Dev Cell* 45: 289-301

Yazici D, Sezer H (2017) Insulin Resistance, Obesity and Lipotoxicity. *Adv Exp Med Biol* 960: 277-304

Zamora A, Nougue M, Verdu L, Balzan E, Draia-Nicolau T, Benuzzi E, Pujol F, Baillif V, Lacazette E, Morfoisse F *et al* (2024) 15-Lipoxygenase promotes resolution of inflammation in lymphedema by controlling T(reg) cell function through IFN-beta. *Nat Commun* 15: 221

Zeng J, Sauter ER, Li B (2020) FABP4: A New Player in Obesity-Associated Breast Cancer. *Trends Mol Med* 26: 437-440

Zhou H, Urso CJ, Jadeja V (2020) Saturated Fatty Acids in Obesity-Associated Inflammation. *J Inflamm Res* 13: 1-14

**Figure legends**

**Fig. 1.** **Reduced PUFA/SFA ratio in secondary lymphedema patients compared to non-lymphedema controls.** Plasma samples from secondary lymphedema patients (*n*=57) and non-lymphedema controls (*n*=22) were analyzed to assess the polyunsaturated fatty acid (PUFA) to saturated fatty acid (SFA) ratio across different lipid fractions. Scatter plots showing individual PUFA/SFA ratios for (**A**) phospholipids (PLs), (**B**) triglycerides (TGs), (**C**) cholesteryl esters (CEs), and (**D**) free fatty acids (FFAs). Pearson correlation analysis indicates no significant relationship between the PUFA/SFA ratio of (**E**) PLs, (**F**) TGs, (**G**) CEs and (**H**) FFAs and body mass index (BMI) in lymphedema patients. Data are presented as mean ± SEM. Statistical analysis: two-tailed unpaired t-test. Significance: \*P < 0.05, \*\*\*P < 0.001. *n* represents the number of patients.

**Fig. 2.High saturated fat diet induces endoplasmic reticulum (ER) stress and prolongs tail lymphedema in a mouse model.** Lymphedema (LE) was induced via lymphatic ablation in the tails of mice maintained on a standard chow diet (CD), a high-fat diet (HFD), or a high-saturated fat diet (HSFD). Sham surgery involved only skin incision. (**A**) Representative images of mouse tails from each dietary group at day 28 post-surgery. (**B**) Representative H&E staining of tail tissues from sham and lymphedema mice across dietary groups, illustrating differences in tail swelling. Scale bars: 500 μm. (**C**) Tail volume measurements over time, showing significantly prolonged swelling in HSFD-fed mice compared to CD and HFD groups. The lymphedema volume curve for CD-fed mice peaks at days 16–22, followed by spontaneous resolution. (**D**) Representative immunofluorescence staining of LYVE-1-positive cells (green) and markers of ER stress (sXBP-1, CHOP) or apoptosis (TUNEL) (red) in tail tissues from sham or lymphedema mice across diets, 28 days post-surgery. DAPI stains the nucleus (blue). Scale bars: 50 μm. Scatter plots showing (**E, H**) sXBP-1+ LYVE-1+ colocalization and perilymphatic sXBP-1 intensities, (**F, I**) CHOP+ LYVE-1+ colocalization and perilymphatic CHOP intensities, and (**G, J**) TUNEL+ LYVE-1+ colocalization and perilymphatic TUNEL intensities comparing the groups. Data are presented as mean ± SEM. Statistical analysis: two-way ANOVA with Šídák’s post hoc test for panel C (*n*=5). Significance: \*P < 0.05 Lymphedema HSFD vs Lymphedema CD, **#**P < 0.05 Lymphedema HFD vs Lymphedema CD; one-way ANOVA with Tukey’s post hoc test for panels E–J (*n*=4-5). Significance: \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001, \*\*\*\*P < 0.0001. *n* represents the number of mice. LYVE-1: lymphatic vessel endothelial hyaluronan receptor-1; sXBP-1: spliced X-box binding protein 1; CHOP: C/EBP homologous protein; TUNEL: terminal deoxynucleotidyl transferase dUTP nick end labeling; DAPI: 4′,6-diamidino-2-phenylindole.

**Fig. 3. Stearic acid promotes apoptosis in lymphatic endothelial cells via reactive oxygen species (ROS).** (**A**) Human dermal lymphatic endothelial cells (HDLECs) were treated with increasing concentrations of stearic acid (SA) for 24 hours. Cell viability was assessed by trypan blue exclusion assay. (**B**) Human Umbilical Vein Endothelial Cells (HUVECs), Human Dermal Microvascular Endothelial Cells (HDMECs), and HDLECs were treated with 10 μM of SA and 250 μM of palmitic acid (PA) for 48 hours. Cell viability was measured by trypan blue exclusion assay. (**C**) Quantification of annexin V/7-AAD-positive HDLECs after 24 hours of SA treatment. (**D**) Quantification of MitoSOX-positive HDLECs, indicating mitochondrial ROS levels following SA treatment for 24 hours. (**E**) Quantification of DHE-positive HDLECs, measuring cytosolic ROS levels after 24 hours of SA treatment. (**F**) HDLECs pretreated with α-tocopherol (200 µg/mL) 1 hour before SA treatment, with cell viability evaluated by trypan blue assay 24 hours later. Data are presented as mean ± SEM from n=3 independent experiments. Statistical analysis: one-way ANOVA with Tukey’s post hoc test. Significance: \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001, \*\*\*\*P < 0.0001. MitoSOX: mitochondrial superoxide; DHE: dihydroethidium.

**Fig. 4. Oxidative stress potentiates stearic acid-induced apoptotic cell death in lymphatic endothelial cells.** (**A**) Representative immunofluorescence staining of 8-OHdG (red), a marker of oxidative DNA damage, colocalized with LYVE-1-positive cells (green) in tail tissues of mice with lymphedema (LE) fed a chow diet (CD) or high saturated-fat diet (HSFD) 28 days post-surgery. DAPI stains the nucleus (blue). Scale bars: 50 μm. (**B**) Scatter plots showing 8-OHdG+ LYVE-1+ colocalization (*n*=4-5 mice). (**C**) Quantification of annexin V/7-AAD-positive HDLECs pre-treated with 10 µM of stearic acid (SA) for 1 hour, followed by 300 µM of hydrogen peroxide (H₂O₂) for 24 hours (*n=3* independent experiments). (**D, E**) Quantification of mitochondrial and intracellular reactive oxygen species (ROS) using MitoSOX Red and DHE staining, respectively (*n*=3-4independent experiments). Data are presented as mean ± SEM. Statistical analysis: one-way ANOVA with Tukey’s post hoc test for panels B–E. Significance: \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001, \*\*\*\*P < 0.0001. 8-OHdG: 8-hydroxy-2' -deoxyguanosine; LYVE-1: lymphatic vessel endothelial hyaluronan receptor-1; DAPI: 4′,6-diamidino-2-phenylindole; MitoSOX: mitochondrial superoxide; DHE: dihydroethidium; Bcl-2: B-cell leukemia/lymphoma 2 protein; Mcl-1: myeloid cell leukemia sequence 1; PARP-1: poly(ADP-Ribose) polymerase 1.

**Fig. 5. Transition from high saturated fat diet (HSFD) to chow diet (CD) prevents prolonged tail lymphedema induced by HSFD in a mouse model.** (**A**) Tail volume measurements of mice with lymphedema (LE) over time, demonstrating that the significantly prolonged swelling observed in HSFD-fed mice is prevented when the diet is transitioned from HSFD to CD (HSFD → CD) starting 6 days after surgical lymphatic ablation. (**B**) Scatter plots showing the changes in tail volume 28 days post lymphatic surgery. (**C**) Representative immunofluorescence staining of LYVE-1-positive cells (green) and markers of ER stress (sXBP-1, CHOP), and apoptosis (TUNEL) (red) in tail tissues from lymphedema mice across diets, 28 days post-surgery. DAPI stains the nucleus (blue). Scale bars: 50 μm. Scatter plots showing (**D, G**) sXBP-1+ LYVE-1+ colocalization and perilymphatic sXBP-1 intensities, (**E, H**) CHOP+ LYVE-1+ colocalization and perilymphatic CHOP intensities, and (**F, I**) TUNEL+ LYVE-1+ colocalization and perilymphatic TUNEL intensities comparing the groups. Data are presented as mean ± SEM from n=5 mice. Statistical analysis: two-way ANOVA with Šídák’s post hoc test for panel A. Significance: \*P < 0.05 Lymphedema HSFD vs Lymphedema CD, #P < 0.05 Lymphedema HSFD vs Lymphedema HSFD → CD; one-way ANOVA with Tukey’s post hoc test for panels B and D–I. Significance: \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001, \*\*\*\*P < 0.0001. LYVE-1: lymphatic vessel endothelial hyaluronan receptor-1; sXBP-1: spliced X-box binding protein 1; CHOP: C/EBP homologous protein; TUNEL: terminal deoxynucleotidyl transferase dUTP nick end labeling; DAPI: 4′,6-diamidino-2-phenylindole.

**Fig. 6. Inhibition of FABP4 attenuates stearic acid-induced lipotoxicity and endoplasmic reticulum (ER) stress in lymphatic endothelial cells.** (**A**) Circulating levels of fatty acid-binding protein 4 (FABP4) measured by ELISA in plasma samples from patients with lymphedema (n=51) and non-lymphedema controls (n=18). (**B**) Quantification of cell death (trypan blue assay) in HDLECs treated with SA (50 µM) or palmitic acid (PA, 250 µM) with or without the FABP4 inhibitor BMS-309403 (BMS, 5 µM) pre-treatment (n=4 independent experiments). (**C**) Representative western blot of ER stress markers (sXBP1 and CHOP) in HDLECs treated with SA at increasing concentrations (10–50 µM) with or without BMS pre-treatment. (**D**) Representative immunofluorescence images of HDLECs treated with SA and BMS showing FABP4 (red) and the endoplasmic reticulum marker calreticulin (green). DAPI stains the nucleus (blue). Scale bars: 50 µm. (**E**) Colocalization quantification between FABP4 and calreticulin using Pearson’s correlation coefficient, showing no significant differences between treatment groups (n=3 independent experiments). (**F**) Quantification of cell death in HDLECs transfected with siFABP4 or scrambled siRNA (Sc-siRNA), with or without SA treatment, showing reduced cell death following FABP4 knockdown (n=6 independent experiments). (**G**) Western blot confirming FABP4 knockdown in HDLECs transfected with FABP4-targeting siRNA (siFABP4), with no effect on FABP5 expression. Data are presented as mean ± SEM. Statistical analysis: two-tailed unpaired t-test for panel A; one-way ANOVA with Tukey’s post hoc test for panels B, E, and F. Significance: \*\*P < 0.01, \*\*\*P < 0.001, \*\*\*\*P < 0.0001. FABP4: fatty acid binding protein 1; sXBP-1: spliced X-box binding protein 1; CHOP: C/EBP homologous protein; DAPI: 4′,6-diamidino-2-phenylindole.

**Fig. 7. FABP4 inhibition attenuates prolonged tail lymphedema induced by high saturated fat diet in a mouse model.** (**A**) Tail volume measurements over time in mice with lymphedema (LE), showing that prolonged swelling induced by HSFD is significantly reduced with treatment using the FABP4 inhibitor BMS-309403 (HSFD + BMS) compared to HSFD + PBS controls. (**B**) Scatter plots showing the changes in tail volume 28 days post-lymphatic surgery. (**C**) Representative immunofluorescence staining of LYVE-1-positive cells (green) and markers of ER stress (sXBP-1, CHOP) and apoptosis (TUNEL) (red) in tail tissues from lymphedema mice across diets, 28 days post-surgery. DAPI stains the nucleus (blue). Scale bars: 25 μm. Scatter plots showing (**D, G**) sXBP-1+ LYVE-1+ colocalization and perilymphatic sXBP-1 intensities, (**E, H**) CHOP+ LYVE-1+ colocalization and perilymphatic CHOP intensities, and (**F, I**) TUNEL+ LYVE-1+ colocalization and perilymphatic TUNEL intensities comparing the groups. Data are presented as mean ± SEM from *n*=3-7 mice. Statistical analysis: two-way ANOVA with Šídák’s post hoc test for panel A; one-way ANOVA with Tukey’s post hoc test for panels B and D–I. Significance: \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001, \*\*\*\*P < 0.0001. LYVE-1: lymphatic vessel endothelial hyaluronan receptor-1; sXBP-1: spliced X-box binding protein 1; CHOP: C/EBP homologous protein; TUNEL: terminal deoxynucleotidyl transferase dUTP nick end labeling; DAPI: 4′,6-diamidino-2-phenylindole.

**Fig. 8. Schematic representation of the role of saturated fatty acids (SFAs) and fatty acid-binding protein 4 (FABP4) in secondary lymphedema-associated lipotoxicity.** In patients with secondary lymphedema, an altered plasma fatty acid profile characterized by a decreased polyunsaturated fatty acid (PUFA) to SFA ratio and increased FABP4 levels is observed. Elevated SFAs, such as stearic acid (SA), induce reactive oxygen species (ROS) production, endoplasmic reticulum (ER) stress, and apoptosis in lymphatic endothelial cells. This is mediated through the activation of ER stress pathways, leading to CHOP-mediated apoptosis. FABP4, elevated in lymphedema patients, facilitates SA-induced apoptosis, and its pharmacological inhibition (e.g., BMS-309403) reduces apoptosis and mitigates lymphedema-associated tissue damage and swelling. These findings underscore the role of SFAs and FABP4 in lymphedema pathogenesis and suggest dietary and FABP4-targeted therapeutic strategies. Figure created with Biorender.

**Expanded View legends**

**Figure EV1. Fatty acid composition in plasma lipid fractions of lymphedema patients.** Plasma samples from lymphedema patients (*n*=57) and non-lymphedema controls (*n*=22) were analyzed to assess the distribution of saturated (SFA), unsaturated (UFA), monounsaturated (MUFA), and polyunsaturated fatty acids (PUFA) across major lipid classes: (**A**) phospholipids (PLs), (**B**) triglycerides (TGs), (**C**) cholesterol esters (CEs), and (**D**) free fatty acids (FFAs). (**E–H**) Relative abundance of key fatty acid species—palmitic acid (16:0), stearic acid (18:0), oleic acid (18:1n9), linoleic acid (18:2n6), and docosahexaenoic acid (22:6n3)—within each lipid fraction: (**E**) PLs, (**F**) TGs, (**G**) CEs, and (**H**) FFAs. Data are presented as mean ± SEM. Statistical analysis: two-way ANOVA with Šídák’s post hoc test. Significance: \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001, \*\*\*\*P < 0.0001. *n* represents the number of patients.

**Figure EV2. PUFA/SFA ratio and fatty acid composition in plasma total fatty acids of mice fed different diets.** (**A**) PUFA/SFA ratio in plasma total fatty acids from mice fed a chow diet (CD), high-fat diet (HFD), or high saturated fat diet (HSFD). (**B**) Proportions of individual fatty acids: palmitic acid (16:0), stearic acid (18:0), oleic acid (18:1n9), linoleic acid (18:2n6), and docosahexaenoic acid (22:6n3). (**C**) Representative images of tail tissue from sham and lymphedema (LE) mice fed a high-fat diet, stained for LYVE-1 (green), sXBP-1, CHOP, or TUNEL (red), and DAPI (blue). (**D–F)** Quantification of sXBP-1, CHOP, and TUNEL signal colocalized with LYVE-1 positive cells. (**G–I**) Quantification of perilymphatic signal for sXBP-1, CHOP, and TUNEL, showing elevated ER stress and apoptosis in lymphedema tissue. Data are presented as mean ± SEM from *n*=4 mice. Statistical analysis: one-way ANOVA with Tukey’s post hoc test for panel A; two-way ANOVA with Šídák’s post hoc test for panel B; two-tailed unpaired t-test for panels D–I. Significance: \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001, \*\*\*\*P < 0.0001. *n* represents the number of mice. PUFA: polyunsaturated fatty acid; SFA: saturated fatty acid; LYVE-1: lymphatic vessel endothelial hyaluronan receptor-1; sXBP-1: spliced X-box binding protein 1; CHOP: C/EBP homologous protein; TUNEL: terminal deoxynucleotidyl transferase dUTP nick end labeling; DAPI: 4′,6-diamidino-2-phenylindole. Scale bars: 50 μm.

**Figure EV3. Stearic acid impairs lymphatic endothelial migration and vessel sprouting.** (**A–D**) Scratch wound assay in human dermal lymphatic endothelial cells (HDLECs) and human dermal microvascular endothelial cells (HDMECs) treated with vehicle or stearic acid (SA, 10 µM). (**A**) Representative brightfield images of HDLECs at 0, 16, and 32 hours post-scratch with wound edges outlined in cyan. Scale bars: 200 μm. (**B**) Quantification of wound area over time showing significantly impaired wound closure in SA-treated HDLECs (*n*=4 independent experiments). (**C**) Representative brightfield images of HDMECs at 0, 24, and 48 hours post-scratch with wound edges outlined in cyan. Scale bars: 200 μm. (**D**) Wound area quantification shows minimal effect of SA on HDMEC migration (*n*=4 independent experiments). (**E**) Lymphatic ring assay using mouse thoracic duct segments embedded in collagen. Vehicle-treated segments show robust endothelial sprouting (red arrows), while SA-treated rings exhibit inhibition of outgrowth and vessel formation (*n*=3 mice). Scale bars: 200 μm (top images) and 100 μm (bottom images). Data are presented as mean ± SEM. Statistical analysis: one-way ANOVA with Tukey’s post hoc test. Significance: \*P < 0.05.

**Figure EV4. FABP4 inhibition or dietary transition reduces lipid accumulation and adipocyte expansion in lymphedematous tissue.** (**A–B**) Oil Red O staining of tail tissue from sham and lymphedema (LE) mice maintained on a high saturated fat diet (HSFD) or treated with the FABP4 inhibitor BMS-309403 (HSFD + BMS) or switched to a control diet (HSFD → CD) after lymphatic injury. (**A**) Representative images showing lipid accumulation (red) in lymphedematous tails. Scale bars: 100 μm. (**B**) Quantification of Oil Red O positive area reveals increased lipid deposition in lymphedema tissue under HSFD, which is significantly reduced by BMS treatment or dietary transition (*n*=4 mice). (**C–E**) Immunofluorescence staining for FABP4 (red) in tail tissue from CD, HSFD-, HSFD + BMS-, or HSFD → CD-fed lymphedema mice. DAPI (blue) marks nuclei. (**C**) Representative images showing increased FABP4 positive adipocytes in HSFD-fed mice. Scale bars: 50 μm. (**D**) Quantification of FABP4 positive adipocyte number. (**E**) Quantification of FABP4 positive adipocyte area (*n*=4 mice). (**F**) Circulating FABP4 levels measured in mice with lymphedema, showing increased plasma FABP4 in HSFD-fed mice and partial reduction with BMS treatment (*n*=7 mice). Data are presented as mean ± SEM. Statistical analysis: one-way ANOVA with Tukey’s post hoc test. Significance: \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001, \*\*\*\*P < 0.0001. HSFD: high saturated fat diet; CD: control diet; FABP4: fatty acid-binding protein 4; BMS: BMS-309403; DAPI: 4′,6-diamidino-2-phenylindole.

**Figure EV5. FABP4 inhibition and diet transition reduce immune cell accumulation in lymphedematous tissue.** Representative immunohistochemistry images showing (**A**) F4/80 positive macrophages and (**B**) CD4 positive T cells in the perilymphatic region of tail tissue from mice with lymphedema fed a high saturated fat diet (HSFD), treated with the FABP4 inhibitor BMS-309403 (HSFD + BMS), or switched to a control diet after lymphatic injury (HSFD → CD). Quantification of immune cell infiltration for (**C**) F4/80 positive macrophages and (**D**) CD4 positive T cells. HSFD-fed mice exhibited significantly higher perilymphatic immune cell infiltration, which was attenuated by FABP4 inhibition or dietary transition. Data are presented as mean ± SEM from *n*=5 mice. Statistical analysis: one-way ANOVA with Tukey’s post hoc test. Significance: \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001. HSFD: high saturated fat diet; CD: control diet; FABP4: fatty acid-binding protein 4.